GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
26 mars 2024 17h00 HE
|
GT Biopharma, Inc.
Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H...
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders
06 déc. 2023 09h30 HE
|
GT Biopharma, Inc.
The deadline for stockholders to vote (or change their vote) is 11:59 p.m. EST on Sunday, December 17, 2023 BRISBANE, California, Dec. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma,...
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
04 déc. 2023 09h30 HE
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
GT Biopharma Names Charles J. Casamento to the Board of Directors
04 mai 2023 09h05 HE
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, May 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based...
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
10 nov. 2022 15h15 HE
|
GT Biopharma, Inc.
Poster #1: Tri-specific killer engagers target natural killer cells towards mesotheliomaPoster #2: Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel...
GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update
31 oct. 2022 17h15 HE
|
GT Biopharma, Inc.
Announced two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)$20.8 million in cash, cash equivalents and short-term investments as of September 30,...